Biosynex SA (EPA:ALBIO)

France flag France · Delayed Price · Currency is EUR
0.8860
-0.0040 (-0.45%)
Jun 19, 2026, 5:35 PM CET
Market Cap16.33M -33.8%
Revenue (ttm)95.19M -5.9%
Net Income-58.22M
EPS-3.16
Shares Out 18.43M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume1,480
Open0.8840
Previous Close0.8900
Day's Range0.8840 - 0.9100
52-Week Range0.4550 - 1.5700
Beta0.83
AnalystsStrong Buy
Price Target3.60 (+306.32%)
Earnings DateMay 14, 2026

About Biosynex

Biosynex SA designs, manufactures, and distributes rapid diagnostic tests to patients and healthcare professionals in France and internationally. The company develops and markets IVDs in the form of RDTs and TRODs, immunoblot, molecular biology, and POC for screening, diagnosis, and prevention. It also provides thermometers, tensiometers, oximetry, hearing protection products, oral and dental hygiene products, self-tests, thermal pads, inhalation chambers, and thermotherapy products, as well as anti-mosquito bracelets and waterproof, moisturizi... [Read more]

Sector Healthcare
Founded 2005
Employees 397
Stock Exchange Euronext Paris
Ticker Symbol ALBIO
Full Company Profile

Financial Performance

In 2025, Biosynex's revenue was 95.19 million, a decrease of -5.90% compared to the previous year's 101.17 million. Losses were -58.22 million, 34.4% more than in 2024.

Financial Statements